Skip to main content

Advertisement

SpringerLink
Log in

Long-term therapeutic effects and safety of tacrolimus added to methotrexate in patients with rheumatoid arthritis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

To assess the long-term safety and efficacy of tacrolimus (TAC) used in combination with oral methotrexate (MTX) in patients with rheumatoid arthritis (RA) whose disease remains active despite treatment with MTX alone. The clinical courses of 24 RA patients who received TAC added to MTX from a single center were analyzed retrospectively. The disease activity was evaluated by the DAS28-ESR(3) every 12 months after the addition of TAC, and side effects were evaluated for 3 years. At 3 years after starting the treatment, TAC was still being used by 19 patients (79 %). The causes of discontinuation were an inadequate response (3 cases), oral ulcers and elevation of creatinine (1 case), and worsening of interstitial pneumonia (1 case). No death was registered. The DAS28-ESR(3) was decreased from 4.81 to 3.41 after 3 years of treatment. The doses of prednisolone were decreased from 5.1 mg/day to 3.2 mg/day after 3 years. In patients whose active RA persists despite treatment with MTX, TAC in combination with MTX is safe and well tolerated and provided clinical benefit for a long time in this single-center retrospective study. Further studies are required to confirm the safety and efficacy of this combination therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M et al (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European standing committee for international clinical studies including therapeutics (eSCISIT). Ann Rheum Dis 66:34–45

    Article  PubMed  CAS  Google Scholar 

  2. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975

    Article  PubMed  CAS  Google Scholar 

  3. Bijlsma JW, Jacobs JW (2009) Methotrexate: still the anchor drug in RA treatment. Joint Bone Spine 76:452–454

    Article  PubMed  Google Scholar 

  4. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C et al (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70:266–271

    Article  PubMed  CAS  Google Scholar 

  5. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361

    Article  PubMed  CAS  Google Scholar 

  6. Cope AP (2008) T cells in rheumatoid arthritis. Arthritis Res Ther 10:S1

    Article  PubMed  Google Scholar 

  7. Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ et al (2004) Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford) 43:992–999

    Article  CAS  Google Scholar 

  8. Kawai S, Tanaka K, Ohno I, Utsunomiya K, Seino Y (2008) Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients. Mod Rheumatol 18:345–353

    Article  PubMed  CAS  Google Scholar 

  9. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T et al (2002) Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 46:2020–2028

    Article  PubMed  CAS  Google Scholar 

  10. Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ et al (2003) Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum 48:2763–2768

    Article  PubMed  CAS  Google Scholar 

  11. Morita Y, Sasae Y, Sakuta T, Satoh M, Sasaki T, Kashihara N (2008) Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. Mod Rheumatol 18:379–384

    Article  PubMed  CAS  Google Scholar 

  12. Hesselink DA, Bouamar R, van Gelder T (2010) The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 32:387–393

    Article  PubMed  CAS  Google Scholar 

  13. Suzuki K, Kameda H, Amano K, Nagasawa H, Takei H, Sekiguchi N et al (2009) Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis. Rheumatol Int 29:431–436

    Article  PubMed  CAS  Google Scholar 

  14. McCurry J (2004) Japan deaths spark concerns over arthritis drug. Lancet 363:461

    Article  PubMed  Google Scholar 

  15. Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Otsuka T et al (2009) Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 48:1265–1268

    Article  Google Scholar 

  16. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF (2005) The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 44:61–66

    Article  CAS  Google Scholar 

  17. Shidara K, Hoshi D, Inoue E, Yamada T, Nakajima A, Taniguchi A et al (2010) Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol 20:280–286

    Article  PubMed  Google Scholar 

  18. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, Jouanneau C, Jaudon MC, Maksud P et al (2002) Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 13:2962–2968

    Article  PubMed  CAS  Google Scholar 

  19. Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L (2004) P-glycoprotein in autoimmune diseases. Autoimmun Rev 3:188–192

    Article  PubMed  CAS  Google Scholar 

  20. Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N et al (2010) Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol 37:512–520

    Article  PubMed  CAS  Google Scholar 

  21. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y (2008) Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 67:380–388

    Article  PubMed  CAS  Google Scholar 

  22. Diamanti AP, Rosado M, Germano V, Scarsella M, Giorda E, Podesta E et al (2011) Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: modulation of P-glycoprotein function. Clin Immunol 138:9–13

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan

    Takeyuki Kanzaki, Kimito Kawahata, Hiroko Kanda, Keishi Fujio, Kanae Kubo, Lisa Akahira, Kazuya Michishita, Toshiki Eri & Kazuhiko Yamamoto

Authors
  1. Takeyuki Kanzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimito Kawahata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroko Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keishi Fujio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kanae Kubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lisa Akahira
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuya Michishita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshiki Eri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuhiko Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kimito Kawahata.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanzaki, T., Kawahata, K., Kanda, H. et al. Long-term therapeutic effects and safety of tacrolimus added to methotrexate in patients with rheumatoid arthritis. Rheumatol Int 33, 871–877 (2013). https://doi.org/10.1007/s00296-012-2465-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-012-2465-6

Keywords

Search

Navigation